Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use

Area of Science:

• Medical Physics
• Radiochemistry
• Oncology

Background:

• Alpha-particle emitting radionuclides are crucial for cancer therapy due to their high energy and short range.
• Radium-224 (224Ra) is being investigated for treating micrometastatic disease.
• Calcium carbonate (CaCO3) microparticles labeled with 224Ra are a potential local therapy for peritoneal cavity cancers.

Purpose of the Study:

• To investigate the diffusion of 220Rn and re-adsorption of 212Pb from 224Ra-labeled CaCO3 microparticles.
• To evaluate the impact of these processes on therapeutic efficacy in a preclinical cancer model.

Main Methods:

• Comparison of 220Rn diffusion in 224Ra-CaCO3 suspensions versus 224Ra solutions.
• Assessment of 212Pb re-adsorption onto CaCO3 microparticles under simulated in vivo conditions.
• Evaluation of therapeutic efficacy of differently labeled 224Ra-CaCO3 microparticles in mice with ovarian cancer xenografts.

Main Results:

• Diffusion of 220Rn was reduced in 224Ra-CaCO3 suspensions compared to 224Ra solutions.
• Over 70% of 212Pb was re-adsorbed onto CaCO3 microparticles at concentrations above 1 mg/mL.
• Therapeutic benefits were similar for surface-adsorbed and bulk-incorporated 224Ra-CaCO3 microparticles in mice.

Conclusions:

• The release of 220Rn and re-adsorption of 212Pb are key characteristics of 224Ra-labeled CaCO3 microparticles for radiotherapy.
• 220Rn diffusion may extend the therapeutic alpha-particle dose range.
• 212Pb re-adsorption can improve retention in the peritoneal cavity, enhancing localized treatment.